$EXEL News Article - Exelixis Announces U.S. FDA A
Post# of 73
(Total Views: 334)
Posted On: 01/22/2021 1:30:48 PM
$EXEL News Article - Exelixis Announces U.S. FDA Approval of CABOMETYX (cabozantinib) in Combination with OPDIVO (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma https://marketwirenews.com/news-releases/exel...87412.html
(0)
(0)Exelixis Inc. (EXEL) Stock Research Links
My Twitter: WhyteStocks
Scroll down for more posts ▼